RESEARCH PAPER

Noradrenaline stimulates cell proliferation by suppressing potassium channels via G\textsubscript{i/o}-protein-coupled \(\alpha\textsubscript{1B}\)-adrenoceptors in human osteoblasts

D Kodama and A Togari

Department of Pharmacology, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan

BACKGROUND AND PURPOSE

Recent studies demonstrated that the sympathetic nervous system regulates bone metabolism via \(\beta\textsubscript{2}\)-adrenoceptors. Although \(\alpha\)-adrenoceptors are also expressed in osteogenic cells, their functions in bone metabolism have been less studied. We previously demonstrated that noradrenaline suppressed potassium currents via \(\alpha\textsubscript{1B}\)-adrenoceptors in the human osteoblast SaM-1 cell line. The aim of this study was to investigate the signal transduction pathway and the physiological role of noradrenaline in human osteoblasts in more detail.

EXPERIMENTAL APPROACH

To investigate signal transduction through \(\alpha\textsubscript{1B}\)-adrenoceptors, we used whole-cell patch clamp recording and Ca fluorescence imaging. Potassium channels regulate membrane potential and cell proliferation activity in non-excitable cells, so we evaluated cell proliferation activity by BrdU incorporation and WST assay.

KEY RESULTS

In SaM-1 cells, bath-applied noradrenaline elevated intracellular Ca\textsuperscript{2+} concentration and this effect was abolished by both chloroethylclonidine, an \(\alpha\textsubscript{1B}\)-adrenoceptor antagonist, and U73122, a PLC inhibitor. However, the inhibitory effect of noradrenaline on whole-cell current was unaffected by U73122. In contrast, in cells pretreated with either Pertussis toxin, a G\textsubscript{i/o}-protein-coupled receptor inhibitor, or gallein, a G\textsubscript{bg}-protein inhibitor, the inhibitory effect of noradrenaline on whole-cell current was significantly suppressed. Noradrenaline-induced enhancement of cell proliferation was inhibited by CsCl, a non-selective potassium channel blocker, gallein and H89, a PKA inhibitor, but not by U73122.

CONCLUSIONS AND IMPLICATIONS

Noradrenaline facilitated cell proliferation by regulation of potassium currents in human osteoblasts via G\textsubscript{i/o}-protein-coupled \(\alpha\textsubscript{1B}\)-adrenoceptors, not via coupling to Gq-proteins.

Abbreviations

\(\alpha\)-MEM, \(\alpha\)-modified minimum essential medium; BK channel, large-conductance calcium-activated potassium channel; BrdU, 5-bromo-2\textsuperscript{′}-deoxyuridine; CCK-8, cell counting kit-8; CEC, chloroethylclonidine; CREB, cAMP response element binding protein; ERG channel, ether-a-go-go-related gene channel; GIRK, G-protein-gated inward rectifying potassium channel; MC3T3-E1, mouse calvaria-derived osteoblastic cells; PDL, population doubling level; PI–PLC, phosphoinositide-PLC; PTX, Pertussis toxin; RANKL, receptor activator of NF-\(\kappa\)B ligand; SaM-1, human periostium-derived osteoblastic cells; TEA, tetraethylammonium; TREK-1, TWIK-related potassium channel 1; WST, water-soluble tetrazolium
Introduction

Bones are continuously resorbed by osteoclasts and formed by osteoblasts, and bone mass is maintained by the balance between their functions. In recent years, many studies have demonstrated that the sympathetic nervous system is involved in bone metabolism (Cherruau et al., 1999; Elefteriou et al., 2005; Todari and Arai, 2008; He et al., 2011). Bone loss can be induced by continuously high sympathetic tone and this is reversed by β-adrenoceptor blockade (Bonnet et al., 2008; Sato et al., 2010). Previous studies, including ours, showed that mRNAs of both α- and β-adrenoceptors were expressed in human osteoblasts (Togari et al., 1997; Togari, 2002; Huang et al., 2009). Although many studies have suggested that up-regulation of osteoclastogenesis and osteoclastic activity via β-adrenoceptors enhanced bone resorption (Arai et al., 2003; Elefteriou et al., 2005; Kondo and Todari, 2011), the physiological role of α-adrenoceptors in bone metabolism has been less well studied. Adrenaline stimulated cell proliferation and differentiation via α₁-adrenoceptors in MC3T3-E1 osteoblast-like cells (Suzuki et al., 1998; 2001). The expression levels of osteoprotegerin and receptor activator of NF-κB ligand (RANKL) were increased by α- and β-adrenoceptor agonists (Takeuchi et al., 2001; Nishiura and Abe, 2007; Huang et al., 2009; receptor nomenclature follows Alexander et al., 2011).

In general, GPCRs exert their functions via the phosphoinositide–phospholipase C (PI–PLC) pathway or the cAMP/PKA pathway, but recent studies suggested that ion channels also play important roles downstream of the signal transduction pathway of several GPCRs, including adrenoceptors (Inoue et al., 2001; Marx et al., 2002; Kim et al., 2005; O-uchi et al., 2008). We previously demonstrated that noradrenaline suppressed Cs-sensitive and tetraethylammonium-insensitive (TEA-insensitive) potassium channels via α₁-adrenoceptors in human osteoblasts, SaM-1 cells, by using whole-cell patch clamp recordings (Kodama and Todari, 2010). Several types of potassium channel had been found to regulate membrane potential and cell proliferation (Pardo et al., 2005; Liebau et al., 2006; Henney et al., 2009; Jang et al., 2011). In osteoblasts, blockade of large conductance Ca-activated potassium (BK) channels, ERG channels and TREK-1 channels promoted cell proliferation (Hernandez et al., 2007). The inhibitory effects of noradrenaline on potassium channels in human osteoblasts have not yet been defined.

In the present study, we undertook more detailed investigation of the signal transduction pathway in terms of the effect of noradrenaline and whether it is involved in cell proliferation in human osteoblasts, SaM-1 cells. Pharmacological analysis suggested that both G_{q/10} and G_{i/o}-proteincoupled α₁B-adrenoceptors were expressed in SaM-1 cells, and the latter was involved in the inhibitory effect of noradrenaline on potassium channels. Additionally, G_{i/o}-coupled α₂-adrenoceptors, not those coupled to G_{s}-proteins, participated in noradrenaline-induced enhancement of cell proliferation. These results suggested that noradrenaline regulates cell proliferation via G_{q/10}-protein-coupled α₁B-adrenoceptors by regulating potassium channel activity in human osteoblasts.

Methods

Cell culture

The human osteoblasts used in this study, SaM-1 cells, were provided by Dr Koshihara, who prepared them with informed consent from an explant of ulnar periostium tissue from a 20-year-old male patient who underwent curative surgery (Koshihara et al., 1987). These cells have a mitotic lifespan of 34 population doubling levels (PDLs), and we used them at PDL of 22–24 for our experiments. We confirmed the cells are capable of calcifying at this level (Komoto et al., 2012). The cells were cultured in α-modified minimum essential medium (α-MEM; Invitrogen, Carlsbad, CA) containing 10% FBS (Morerate Biotech, Bulimba, Australia) and 60 μg·mL⁻¹ kanamycin at 37°C in 95% humidified air containing 5% CO₂. The growth media were renewed every 2 days. For optical measurements of intracellular calcium concentration ([Ca²⁺]i) and whole-cell patch clamp recording, they were seeded on a cover slip, 1–2 days before the experiments.

Optical measurements of [Ca²⁺]i

SaM-1 cells were loaded with fluo-3AM (2.5 μM) for 30 min and washed three times with extracellular solution, which contained 124 mM NaCl, 3 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 14 mM d-glucose and 10 mM HEPES (pH adjusted to 7.4 with NaOH), just before use. Then, the glass coverslip was transferred to a superfusion chamber on the stage of a confocal laser scanning microscope (LSM710, Carl Zeiss, Hallbergmoos, Germany). Cells were superfused with extracellular solution at a rate of 2 mL·min⁻¹. The fluorescence was recorded every 2 s at room temperature at an excitation wavelength of 488 nm, and the data were analysed using ZEN 2009 software (Carl Zeiss). Stock solutions of drugs were prepared and diluted 1000-fold into extracellular solution just before use, and they were applied by bath perfusion.

Whole-cell patch clamp recording

SaM-1 cells were seeded on a glass coverslip. After 1–2 days of culture, the glass coverslip was transferred to a superfusion chamber on the stage of an inverted microscope (Axiovert200, Carl Zeiss). Cells were superfused with extracellular solution at 1–1.5 mL·min⁻¹. Whole-cell voltage clamping was performed using patch electrodes (3–5 MΩ) filled with internal solution containing 140 mM KCl, 2 mM MgCl₂, 10 mM HEPES, 0.1 mM EGTA, 3 mM Na₂ATP and 0.3 mM Na₃GTP (pH adjusted to 7.4 with KOH) and Axopatch200B patch clamp amplifier (Axon Instruments, Sunnyvale, CA). In the experiments to investigate the involvement of [Ca²⁺]i, we used internal solution containing 130 mM KCl, 2 mM MgCl₂, 10 mM HEPES, 5 mM EGTA, 3 mM Na₂ATP and 0.3 mM Na₃GTP (pH adjusted to 7.4 with KOH).

The holding potential was –60 mV, and voltage–current relationships were recorded using voltage steps or ramps. In the voltage step protocol, 10 mV voltage steps from –100 to +40 mV from a holding potential of –60 mV for 500 ms were applied. In the voltage ramp protocol, 1 s voltage ramp from...
-100 to +40 mV following 150 ms voltage steps of -100 mV was applied every 10 s. The signals were low-pass filtered at 10 kHz and digitized at 20 kHz for analysis with pClamp9.2 software (Molecular Devices, Silicon Valley, CA). Stock solutions of drugs were prepared and diluted 1000-fold into extracellular solution just before use, and they were applied by bath perfusion.

Cell proliferation assay
5-Bromo-2'-deoxyuridine (BrdU) incorporation. Cell proliferation activity was assessed by BrdU incorporation using Cell Proliferation ELISA, BrdU kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s instructions. Cells were seeded in a 96-well plate at a density of 10,000 cells-per well in 100 µL of culture medium. After 1 day, culture media were replaced with α-MEM containing 2.5% FBS and kanamycin, and then the cells were treated with noradrenaline for 20 h at 37°C. BrdU labelling solution (100 µM) was added at 10 µL-per well, and the cells were incubated for an additional 4 h at 37°C. After this, the labelling media was removed, the cells were fixed and DNA was denatured with FixDenat solution. The cells were incubated with peroxidase-conjugated anti-BrdU antibody for 1.5 h at room temperature. The cells were then washed three times with PBS, followed by the addition of substrate solution (tetraethyl-benzidine) at 100 µL-per well. After 15 min incubation, 1 M H2SO4 was added at 25 µL-per well to stop the peroxidase reaction, and then absorbance of wells was measured at 450 nm using Multiskan FC (Thermo Fisher Scientific, Waltham, MA).

Water-soluble tetrazolium (WST) assay. Cell number was assessed as dehydrogenase activity by using WST-8 (Dojindo, Kumamoto, Japan). In this assay, WST-8 is reduced to water-soluble formazan outside the cells. WST-8 was added at 25 µL-per well in 100 µL of culture medium. After 1 day, culture media were replaced with α-MEM containing 2.5% FBS and kanamycin, and then the cells were treated with noradrenaline for 22.5 h at 37°C. WST-8 solution was added at 10 µL-per well, and the cells were incubated for an additional 1.5 h at 37°C. Then absorbance of wells was measured at 450 nm using Multiskan FC (Thermo Fisher Scientific).

To confirm that the experimental conditions were adequate, the data from non-drug-treated cultures were also recorded in each experiment.

Statistical analysis
All data are expressed as mean ± SEM. In the voltage step protocol, the changes of whole-cell currents in a stable state were evaluated using the paired t-test. In the voltage ramp protocol, the effects of the drugs on whole-cell currents were evaluated by comparing average currents (six traces for 1 min) taken during the peak response to each drug with those before drug application. Cell proliferation activities were evaluated by comparing the data from a control group. The two-tailed t-test combined with Bonferroni’s correction following one-way ANOVA was used for multiple comparisons. Differences with P-values <0.05 were considered significant.

Materials
1-Noradrenaline; chloroethylclonidine (CEC), an α1-adrenoceptor-selective antagonist; U73122, a PLC inhibitor; H89, a PKA inhibitor; clonidine, prazosin and propranolol were purchased from Sigma Aldrich (St. Louis, MO, USA). Pertussis toxin (PTX) was purchased from Merck KGaA (Darmstadt, Germany). CsCl was purchased from Nacalai Tesque (Kyoto, Japan). A Gβγ-protein inhibitor, gallein, was purchased from Tocris Biosciences (Bristol, UK). A calcium fluorophore, fluo-3-AM, was purchased from Dojindo. U73122, gallein and H89 were dissolved in dimethyl sulfoxide. All other chemicals used were of reagent grade.

Results

Involvement of the PI–PLC pathway in the effects of noradrenaline
In Ca2+ fluorescence imaging, elevation of fluo-3-AM fluorescence intensity was induced by bath application of 1 µM noradrenaline in 50.4 ± 6.4% of cells examined and the responses were reproducible on the same cells with repeated application in SaM-1 cells (13 individual experiments; Figure 1A). In the cells pretreated with 100 µM CEC for 45 min at 37°C, bath-applied noradrenaline had no effects on fluorescence (five individual experiments, data not shown). Additionally, the effect of noradrenaline on [Ca2+]i was eliminated by pretreatment with the PLC inhibitor U73122 for 10 min (five individual experiments; Figure 1B). On the other hand, in whole-cell patch clamp recording, the currents induced by voltage steps were significantly reduced and reversal potential was shifted rightwards by 1 µM bath-applied noradrenaline, as shown in our previous study (n = 6; Figure 1C; Kodama and Togari, 2010). The ratios between the current amplitude at the beginning (50 ms) of the pulse and that at the end of pulse (500 ms) were 95.1 ± 2.5% and 90.1 ± 4.4% in the absence and presence of noradrenaline respectively. There was no apparent effect of noradrenaline on the current kinetics. Similarly, in the voltage ramp protocol, whole-cell current was reduced, at 40 mV (n = 7; Figure 1D). These inhibitory effects of noradrenaline on whole-cell current were shown in almost all cells tested (48 of 50 independent experiments, including preliminary data). Bath-applied U73122 slightly suppressed whole-cell current (n = 5), and treatment with noradrenaline following U73122 exhibited a similar extent of inhibition as in the control cells (n = 5; Figure 1D, E). Additionally, the inhibitory effect of noradrenaline was unaffected by using the internal solution containing 5 mM EGTA (n = 5; Figure 1D).

Involvement of Gαi– and Gβγ-protein in the effects of noradrenaline on whole-cell current
We next examined whether Gαi–protein is involved in the inhibitory effect of noradrenaline on whole-cell current. In the cells pretreated with Gαi–coupled receptor inhibitor, PTX, at 150 ng·mL−1 for 24 h, noradrenaline-induced suppression of whole-cell current was significantly attenuated (n = 11, 5, respectively; Figure 2A, D). Treatment with PTX inhibits not only the effect via Gαi–protein but also that via Gβγ-protein.
Involvement of the G_{q/11}-PLC pathway in the inhibitory effect of noradrenaline (NA) on whole-cell current in human osteoblasts. (A and B) Representative traces of \([\text{Ca}^{2+}]_i\) elevation induced by repeated application of noradrenaline in SaM-1 cells. (A) The representative recordings from cells that responded to noradrenaline (B) Representative responses to noradrenaline in the absence (the first application) and presence (the second application) of U73122, an inhibitor of PLC. (C) The averaged voltage–current density relationship recorded by voltage step from \(-100\) to \(+40\) mV. (D) Summary of the influence of the presence of EGTA, a Ca chelator, at 5 mM in the pipette solution and pretreatment with U73122, on the effects of noradrenaline (control, \(n = 7\); EGTA, U73122, \(n = 5\)). (E) Representative averaged traces of six consecutive whole-cell currents during a \(-100\) to \(+40\) mV voltage ramp (a) and time course of whole-cell currents at \(+40\) mV (b). The bars indicate the time points when the averaged traces were recorded. Values are shown as the mean \(\pm\) SEM. *\(P<0.05\), **\(P<0.01\) compared with non-treated control. Each figure is representative data of five independent experiments in panels A, B and E.

(Katz et al., 1992). Then we examined the effect of Gi/o-protein inhibitor, gallein and PKA inhibitor, H89. Pretreatment with gallein at \(10\) \(\mu\)M for 30 min just before the experiment significantly reduced the inhibitory effect of noradrenaline (\(n = 5\); Figure 2B, D). Meanwhile, bath application of H89 at 2.5 \(\mu\)M slightly suppressed whole-cell current (\(n = 5\)), and the inhibitory effect of noradrenaline following H89 application tended to be attenuated (\(n = 5\); Figure 2C, D).

In our previous study, \(\alpha_{2A}\)-adrenoceptors were expressed at a low level in SaM-1 cells (Togari et al., 1997; Togari, 2002). In general, \(\alpha_{2}\)-adrenoceptors are known to be coupled with Gi/o-protein. We then examined the effect of the \(\alpha_2\)-adrenerceptor agonist, clonidine, on whole-cell current. Bath application of clonidine had no obvious effect on the voltage–current relationship (\(n = 5\); Figure 3).

**Effects of adrenoceptor ligands on proliferation in SaM-1 cells**

Cell proliferation activity was evaluated as DNA synthesis by BrdU test, and live cell number was evaluated as
Figure 2

Involvement of G<sub>ai/o</sub>- and G<sub>bg</sub>-proteins in the inhibitory effects of noradrenaline (NA) on whole-cell current. (A–C) Representative averaged traces of six consecutive whole-cell currents during a −100 to +40 mV voltage ramp (a) and time course of whole-cell currents recorded at +40 mV (b) in the cells pretreated with Pertussis toxin (PTX), a G<sub>ai/o</sub>-protein-coupled receptor inhibitor (A), gallein, a G<sub>bg</sub>-protein inhibitor (B), or H89, a PKA inhibitor (C). The bars indicate the time points when the averaged traces were recorded. (D) Summary results of the pretreatment with PTX, gallein or H89 on the effects of noradrenaline (control, n = 11; PTX, gallein, H89, n = 5). Values are shown as the mean ± SEM. **P < 0.01 compared with control. Each figure shows representative data of five independent experiments in panels A, B and C.
dehydrogenase activity by WST assay. In SaM-1 cells, treatment with noradrenaline for 24 h increased BrdU incorporation at a lower dose (0.03 – 0.3 μM) and suppressed it at higher doses (1 μM – 30 μM; n = 8; Figure 4A). On the other hand, noradrenaline only increased formazan formation in WST assays, over the whole concentration range (n = 8; Figure 4D). In the presence of prazosin, an α₁-adrenoceptor antagonist, at 30 μM, noradrenaline induced only decreased effects in both the BrdU test and the WST assay (n = 8; Figure 4B, E). In contrast, in the presence of a β-adrenoceptor antagonist, propranolol, at 10 μM, noradrenaline showed only positive effects in both assays (n = 8; Figure 4C, F). These results suggested that cell proliferation was facilitated via α₁-adrenoceptors and inhibited via β-adrenoceptors.

**Signal pathways involved in the effects of noradrenaline on cell proliferation**

Previously, we demonstrated that Cs-sensitive potassium channels were involved in the inhibitory effects of noradrenaline on whole-cell current (Kodama and Togari, 2010). Here, we have examined whether CsCl affected the increasing effects of noradrenaline via α₁-adrenoceptors. In the presence of 1 mM CsCl and 10 μM propranolol, noradrenaline had no effect on BrdU incorporation and formazan formation (n = 8; Figure 5).

Next, to study whether signal pathways were involved in the positive effects on cell proliferation of noradrenaline, we evaluated BrdU incorporation and formazan formation in the presence of propranolol and gallein, H89, PTX or U73122. The positive effects of noradrenaline in both assays were eliminated by pretreatment with PTX for 24 h (n = 8; Figure 5). Likewise, in the presence of gallein or H89, noradrenaline had no effect in both assays (n = 8; Figure 5). In contrast, in the cells treated with U73122, the positive effect via α₁-adrenoceptors was shown in both assays (n = 8; Figure 5). These results suggested that regulation of potassium current via Gbg-protein-coupled α₁-adrenoceptors was involved in the positive effects on cell proliferation.

**Discussion**

Recent studies have demonstrated that a single subtype of receptor can be associated with different types of heterotrimeric G-proteins (Wenzel-Seifert and Seifert, 2000; Gazi et al., 2003; Cordeaux et al., 2004). It is also suggested that coupling with a particular type of G-protein can be regulated by the location, phosphorylation and expression of GPCRs (Davies et al., 1999; Xiang et al., 2002; Hasseldine et al., 2003). The results presented in this study suggest that α₁B-adrenoceptors can be coupled to both Gbg-protein and Gαbg-protein in human osteoblasts. We previously reported that mRNAs of α₁B-, α₂B- and β₂-adrenoceptors were expressed in SaM-1 cells (Togari et al., 1997; Togari, 2002). Bath application of noradrenaline induced [Ca²⁺]i elevation, and the effect was inhibited by the α₁B-adrenoceptor-selective inhibitor, CEC, and the PLC inhibitor, U73122 (Figure 1A, B). These results indicated that noradrenaline activated the PI-PLC pathway via Gbg-protein-coupled α₁B-adrenoceptors in SaM-1 cells. Meanwhile, noradrenaline-induced suppression of whole-cell current, which was inhibited by pretreatment with CEC in our previous study (Kodama and Togari, 2010), was affected by neither addition of Ca²⁺ chelator to internal solution nor treatment with U73122 (Figure 1D, E). In contrast, the inhibitory effect of noradrenaline on whole-cell current was significantly attenuated by pretreatment with PTX (Figure 2A). However, the α₂-adrenoceptor agonist, clonidine, had no effect on the whole-cell current (Figure 3). These results indicated that noradrenaline inhibited whole-cell current via Gbg-protein-coupled α₁B-adrenoceptors. Although noradrenaline-induced [Ca²⁺]i elevations were detected in about half of SaM-1 cells, the inhibitory effect of noradrenaline on whole-cell current appeared in almost all cells tested. This suggested the possibility that α₁B-adrenoceptors were mainly, but not all, coupled to Gbg-proteins in human osteoblasts.

The effects of Gbg-protein-coupled GPCRs are exerted not only through the Gbg subunit but also through Gβγ subunits. Many studies reported that G-protein-gated inward rectifying
potassium channels (GIRK channels) are regulated by Gβγ subunits (Filippov et al., 2004; Lüscher and Slesinger, 2010). In addition, recent studies reported that Gβγ subunits could interact with several proteins, for example, L-type calcium channels, connexin 43 and GPCR kinase (Ouchi et al., 2008; Sato et al., 2009; Casey et al., 2010). In this study, the inhibitory effect of noradrenaline on whole-cell current was significantly attenuated by pretreatment with the Gβγ-protein inhibitor, gallein (Figure 2B). The inhibitory effect of noradrenaline also tended to be attenuated following application of a PKA inhibitor, H89 (Figure 2C). In SaM-1 cells, the reversal potential of whole-cell current was considered to be less negative. This suggested the possibility that not only potassium channels but also chloride channels, contributed to the whole-cell current. However, noradrenaline-induced suppression was eliminated in the presence of CsCl, a non-selective potassium channel blocker, in our previous study (Kodama and Togari, 2010). Therefore, these results suggested that the potassium channels were inhibited by Gβγ-proteins and were partly regulated by PKA. Although the GIRK channels are a major target of Gβγ-proteins, the whole-cell current suppressed by noradrenaline did not show inward rectification. Zhou et al., (2008) demonstrated that BK channels were inhibited by Gβγ-protein and we previously reported that BK channels were expressed in SaM-1 cells (Hirukawa et al., 2008). However, BK channels are inhibited by TEA and activated by [Ca2+]i elevation (Henney et al., 2009; Lee and Cui, 2010). The inhibition of the current by noradrenaline was seen at cell potentials below −60 mV, and further inhibition was seen over 0 mV (Figure 1C). Additionally, there was no apparent effect of noradrenaline on the current kinetics. These results suggested that the channels inhibited by noradrenaline were non-inactivated, outward rectifying and open at the resting potential. Recent studies demonstrated that the two-pore domain K channel family is responsible for non-inactivated, leak or background, potassium current (Patel and Honoré, 2001) and TREK-1, a mechanosensitive member of the two-pore domain K channels, was expressed and regulated cell proliferation in human osteoblasts (Hughes et al., 2006). The current through TREK-1 is outwardly rectifying and is insensitive to classical potassium channel blockers, including TEA (Patel and Honoré, 2001). However, TREK-1 activity was inhibited by Gαi/o-protein-coupled receptors (Mathie, 2007). Rivard et al. (2009) reported that overexpression of α1β-adrenoceptors decreased outwards potassium

Figure 4
The effects of noradrenaline (NA) on cell proliferation of human osteoblasts through α1- and β-adrenoceptors. (A–C) Effects of noradrenaline on DNA synthesis measured by BrdU incorporation. (A) Dose–response relationship of the effect of noradrenaline (n = 8). (B, C) Effects of noradrenaline in the presence of the α1-blocker prazosin at 30 μM (B) and β-blocker propranolol at 10 μM (C) (n = 8). (D–F) Effects of noradrenaline on water-soluble tetrazolium salt (formazan) formation by dehydrogenase in live cells were assessed by WST assay. (D) Dose–response relationship of the effect of noradrenaline (n = 8). (E, F) Effects of noradrenaline in the presence of prazosin at 30 μM (E) and propranolol at 10 μM (F) (n = 8). Values are shown as the mean ± SEM. *P < 0.05, **P < 0.01 compared with control. Each figure is representative data from three to five independent experiments.
While the results of the BrdU tests indicated DNA synthesis in a dose-dependent manner (Figure 4D).

In WST assays, noradrenaline also increased for DNA synthesis at a low dose and decreased it at a high dose (Figure 4A). Additionally, in the WST assay, positive effects of noradrenaline were inhibited by prazosin and propranolol respectively (Figure 4B, C). These results suggested that cell proliferation in human osteoblasts is bi-directionally regulated by noradrenaline via α1- and β-adrenoceptors. This is consistent with a previous study in human osteoblasts (Huang et al., 2009). A number of studies have demonstrated involvement of β2-adrenoceptors in bone metabolism. In general, the β2-adrenoceptor is coupled with Gβγ-protein and is thought to activate the cAMP/PKA pathway and Fu et al., (2005) demonstrated that β2-adrenoceptors regulated osteoblast proliferation via the cAMP/PKA/CREB signalling pathway in vivo.

As observed with whole-cell current, the positive effects of noradrenaline via α1-adrenoceptors, shown in BrdU tests and WST assays, was inhibited in the presence of CsCl (Figure 5). These results suggested that noradrenaline enhanced cell proliferation by blocking Cs-sensitive potassium channels. Additionally, the positive effects of noradrenaline via α1-adrenoceptors on cell proliferation in both assays were suppressed by inhibition of Gβγ-protein-coupled receptors by PTX, Gβγ-protein by gallein or the cAMP/PKA pathway by H89, but not by inhibition of the PI–PLC pathway by U73122 (Figure 5). These results suggested the possibility that noradrenaline-induced suppressions of potassium channels via Gβγ-protein and the cAMP–PKA pathway were involved in its effect on cell proliferation mediated by α1-adrenoceptors. Suzuki et al. (1998; 2001) reported that adrenaline stimulated cell proliferation and alkaline phosphatase activity and increased type III P3 transporter expression via α1-adrenoceptors, and these effects were inhibited by PTX in MC3T3-E1 osteoblast-like cells. Activation of α1-adrenoceptors induced the expression of RANKL, and this effect was inhibited by a PKC inhibitor (Nishiura and Abe, 2007). Therefore, Gβγ and Gβγ-coupled α1-adrenoceptors are thought to play different roles in osteoblasts.

Both experimental and clinical studies have demonstrated that β-adrenoceptor blockade is effective against osteoporosis accompanied by a highly active sympathetic nervous system (Pasco et al., 2004; Bonnet et al., 2007; 2008; Sato et al., 2010; Yang et al., 2011). There is also a report that α1-adrenoceptor blockade increased the risk of hip/femur fracture (Souverein et al., 2003). Phenylephrine, an α1-adrenoceptor agonist, promotes osteogenesis in bone fracture healing (McDonald et al., 2011). All these reports suggest the possibility that activation of α1-adrenoceptors could lead to a treatment for osteoporosis. The positive effects via α1B-adrenoceptors on osteoblast proliferation might contribute to bone fracture healing and treatment of osteoporosis. However, neither knockout nor overexpression of α1B-adrenoceptors has been reported to result in obvious skeletal phenotypes (Battaglia et al., 2003; Rivard et al., 2009; Docherty, 2010). Detailed analysis of bone metabolism in a pathophysiological state showing high sympathetic tone, for example, in leptin-injected mice, ovariectomized mice or during 20–24 h after treatment with noradrenaline, those from the WST assays indicated cumulative effects on cell proliferation. These differences might account for the divergent results of the BrdU test and the WST assay, at high concentrations of noradrenaline. In the BrdU test, the positive and negative effects of noradrenaline were inhibited by prazosin and propranolol respectively (Figure 4B, C). Additionally, in the WST assay, positive effects of noradrenaline were inhibited by prazosin but not by propranolol (Figure 4E, F). These results suggested that cell proliferation in human osteoblasts is bi-directionally regulated by noradrenaline via α1- and β-adrenoceptors. This is consistent with a previous study in human osteoblasts (Huang et al., 2009). A number of studies have demonstrated involvement of β2-adrenoceptors in bone metabolism. In general, the β2-adrenoceptor is coupled with Gβγ-protein and is thought to activate the cAMP/PKA pathway and Fu et al., (2005) demonstrated that β2-adrenoceptors regulated osteoblast proliferation via the cAMP/PKA/CREB signalling pathway in vivo.

As observed with whole-cell current, the positive effects of noradrenaline via α1-adrenoceptors, shown in BrdU tests and WST assays, was inhibited in the presence of CsCl (Figure 5). These results suggested that noradrenaline enhanced cell proliferation by blocking Cs-sensitive potassium channels. Additionally, the positive effects of noradrenaline via α1-adrenoceptors on cell proliferation in both assays were suppressed by inhibition of Gβγ-protein-coupled receptors by PTX, Gβγ-protein by gallein or the cAMP/PKA pathway by H89, but not by inhibition of the PI–PLC pathway by U73122 (Figure 5). These results suggested the possibility that noradrenaline-induced suppressions of potassium channels via Gβγ-protein and the cAMP–PKA pathway were involved in its effect on cell proliferation mediated by α1-adrenoceptors. Suzuki et al. (1998; 2001) reported that adrenaline stimulated cell proliferation and alkaline phosphatase activity and increased type III P3 transporter expression via α1-adrenoceptors, and these effects were inhibited by PTX in MC3T3-E1 osteoblast-like cells. Activation of α1-adrenoceptors induced the expression of RANKL, and this effect was inhibited by a PKC inhibitor (Nishiura and Abe, 2007). Therefore, Gβγ and Gβγ-coupled α1-adrenoceptors are thought to play different roles in osteoblasts.

Both experimental and clinical studies have demonstrated that β-adrenoceptor blockade is effective against osteoporosis accompanied by a highly active sympathetic nervous system (Pasco et al., 2004; Bonnet et al., 2007; 2008; Sato et al., 2010; Yang et al., 2011). There is also a report that α1-adrenoceptor blockade increased the risk of hip/femur fracture (Souverein et al., 2003). Phenylephrine, an α1-adrenoceptor agonist, promotes osteogenesis in bone fracture healing (McDonald et al., 2011). All these reports suggest the possibility that activation of α1-adrenoceptors could lead to a treatment for osteoporosis. The positive effects via α1B-adrenoceptors on osteoblast proliferation might contribute to bone fracture healing and treatment of osteoporosis. However, neither knockout nor overexpression of α1B-adrenoceptors has been reported to result in obvious skeletal phenotypes (Battaglia et al., 2003; Rivard et al., 2009; Docherty, 2010). Detailed analysis of bone metabolism in a pathophysiological state showing high sympathetic tone, for example, in leptin-injected mice, ovariectomized mice or...
spontaneous hypertensive rats, is required to investigate the physiological role of α₁B-adrenoceptor (Elefteriou et al., 2005; Sato et al., 2010).

In conclusion, the present study suggested that noradrenaline suppressed potassium channels via G_{i/o}-coupled α₁B-adrenoceptors and that the Gβγ-proteins play an important role in this effect. Additionally, this effect was involved in the noradrenaline-induced increase in proliferation of human osteoblasts, SaM-1 cells. These results will aid understanding of the mechanism behind the regulation of bone metabolism by the sympathetic nervous system.

Acknowledgements

This work was partly supported by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 21890276 to D.K.) and by a Grant-in-Aid from Strategic Research AGU-Platform Formation (2008-2012).

Conflicts of interest

All authors have no conflicts of interest.

References


